Galecto's $285M Investment Boosts Blood Cancer Treatment

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded10 Nov 2025

Publisherfeeds.acast.com ↗

Handlerec:2198807

Show notes

Galecto Incorporateds stock surged 360% after acquiring Damora Therapeutics, focusing on MPNs. The deal secured $285M, enabling Galecto to advance DMR-zero-zero-one, a potential top-tier treatment, and combine it with GB-three-two-two-six for acute myeloid leukemia. Galecto aims to begin human trials in 2026.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.